AAA
ELVN icon

Affinity Asset Advisors’s Enliven Therapeutics ELVN Stock Holding History

Affinity Asset Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23M Buy
+586,904
New +$16.3M 1.19% 28
2025
Q4 		– Sell
-400,000
Closed -$8.19M – 100
2025
Q3 		$8.19M Hold
400,000
– – 0.71% 38
2025
Q2 		$8.02M Buy
+400,000
New +$7.57M 1.1% 28

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Affinity Asset Advisors's ELVN Position: Q1 2026 in Review

Affinity Asset Advisors opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 586,904 shares worth $23M. The stake represents 1.19% of the portfolio and ranks #28 among its holdings. This is a return to the name: Affinity Asset Advisors previously reported a position in ELVN as recently as Q3 2025.

Affinity Asset Advisors first reported a position in ELVN in Q2 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Affinity Asset Advisors held 586,904 shares of Enliven Therapeutics worth $23M as of Q1 2026.
  • Enliven Therapeutics was a new Affinity Asset Advisors position in Q1 2026.
  • Enliven Therapeutics made up 1.19% of Affinity Asset Advisors's portfolio in Q1 2026, its #28 holding.
  • Affinity Asset Advisors first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.